Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of CM313 in Healthy Subjects
NCT06285227Phase 1Recruiting
- Sponsor
- Keymed Biosciences
- Start
- Mar 2024
- Primary completion
- Apr 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cm313 in multiple myeloma (MM), systemic lupus erythematosus (SLE), immune thrombocytopenia (ITP) and 1 more (5 arms), sponsored by Keymed Biosciences. Primary endpoint: Adverse event. Started Mar 2024; status: recruiting.
02
Drugs
cm313
03
Conditions
multiple myeloma (MM)systemic lupus erythematosus (SLE)immune thrombocytopenia (ITP)lymphoma
Beyond the preview
Go deeper on NCT06285227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06285227.